No evidence package for common commercial routes FDAs briefing found no adequate human studies for the commonly proposed oral, subcutaneous, nasal, or transdermal routes
A 2025 review in Pharmaceuticals put it bluntly: There are obvious differences between the physiologies of rodents and humans
Tirzepatide is given subcutaneously once a week and was examined in four worldwide phase III randomized, placebo-controlled clinical trials as part of the SURMOUNT Program, which also includes lifestyle modification
Detailed Initial Evaluation We begin our process with a thorough assessment of the patients current health, including their medical history, any existing conditions such as diabetes or thyroid disorders, personal habits, metabolic rate, weight, and personal objectives for weight loss